Videos

Asciminib in CML Treatment: Efficacy and Responses Shown in the ASCEMBL Study

Artificial intelligence may help detect tumors both within the prostate and that have spread to areas outside of the prostate, according to Wayne G. Brisbane, MD.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Exploring the Role of Ixazomib in Relapsed/Refractory Multiple Myeloma

A review of promising results from the ASCEMBL study, highlighting asciminib's superior efficacy, well-tolerated profile, and potential impact on chronic myeloid leukemia treatment options.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Managing Cardiovascular Risks in CML Treatment

Key insights on real-world applications of the REMIX study, which evaluated real-world effectiveness and tolerability of the ixazomib-based regimen in relapsed/refractory multiple myeloma.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

REMIX Study: Ixa-Len-Dex for Relapsed/Refractory Myeloma

A panel of experts discusses the challenges and considerations surrounding cardiovascular risks associated with ponatinib treatment for chronic myeloid leukemia, emphasizing the need for multidisciplinary collaboration and individualized treatment strategies.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Selecting Patients Best Suited for AI Prostate Cancer Detection

Outcomes of the REMIX study investigating the effectiveness and tolerability of ixa-len-dex in real-world relapsed/refractory myeloma patients, exploring progression-free survival, overall response rate, and safety.

An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.

Wayne G. Brisbane, MD

September 25th 2023

An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.

AI May Help With MRI Interpretation During Prostate Cancer Detection

Wayne G. Brisbane, MD

September 24th 2023

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.

DESTINY-CRC02 Trial: Trastuzumab Deruxtecan for the Management of mCRC

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

September 22nd 2023

Daniel Ahn, DO, and Tanios Bekaii-Saab, MD, detail the findings of the DESTINY-CRC02 trial, which examined the efficacy of trastuzumab deruxtecan at different dosing levels in breast cancer and gastric cancer patients.

MOUNTAINEER-01 Trial: Tucatinib in Patients With mCRC

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

September 22nd 2023

Christina Wu, MB, BCh, MD, shares the study design and efficacy data of the MOUNTAINEER-01 study, which explored combination tucatinib plus trastuzumab for the treatment of patients with HER2+ metastatic colorectal cancer.

CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times

A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)

A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.

$Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)$

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

Bone Disease Prophylaxis in Patients With Transplant-Eligible NDMM

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with relapsed/refractory multiple myeloma for panel discussion.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse

Expert panelists discuss the options for preventing bone disease in patients with multiple myeloma, including osteonecrosis of the jaw.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma

Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety

An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Dosing Strategies and Disease Control With Ponatinib: The OPTIC Study

Experts discuss dosing strategies and risk factors for arterial occlusive events in ponatinib treatment for chronic myeloid leukemia, emphasizing the importance of balancing disease control and patient safety.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Momelotinib Will ‘Make an Immediate Impact’ in Myelofibrosis With Anemia

An expert explores findings of the OPTIC study, revealing optimal dosing strategies for ponatinib in CML treatment, including insights into dose reduction and patient response based on T315I mutation status.

Ruben A. Mesa, MD, FACP

August 2023 Snap Recap: Chemo Shortages, FDA Approvals in Multiple Myeloma

With the approval of momelotinib by the FDA, the updated use for its role in myelofibrosis will potentially change clinical practice, according to Ruben Mesa, MD.

The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.

Hayley Virgil

Patient Scenario: A 65-Year-Old Man with HER2+ mCRC

The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

Common Testing Strategies for Molecular Markers in mCRC

Daniel Walden, MD, presents the scenario of a 65-year-old man diagnosed with HER2+ metastatic colorectal cancer to the expert panel for discussion.

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

Assessing Frailty in Multiple Myeloma

Experts emphasize the importance of acquiring both tissue and circulating tumor DNA (ctDNA) for molecular testing in patients with metastatic colorectal cancer, address challenges such as lack of tissue and costs, and highlight the role of HER2 as a biomarker.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Treatment Strategies for Patients With Transplant-Ineligible MM

Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Factors for Consideration When Treating Frail Patients With Transplant-Ineligible NDMM

Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM

Focused discussion on tailoring treatment decision-making for patients with multiple myeloma classified as frail.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

The Future of GVHD Treatment

A panel of experts explain how they select between the DRd (daratumumab, lenalidomide, dexamethasone) and VRd (bortezomib, lenalidomide, dexamethasone) treatment regimens for patients with transplant-ineligible newly diagnosed multiple myeloma.

Nelson J. Chao, MD, MBA

Biochemical and Clinical Progression: The Two Faces of Relapsed MM

The panel shares new therapies for the treatment of chronic graft-versus-host disease they look forward to seeing in the future.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope

Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.

Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Vivian G. Oehler, MD;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS